荧光原位杂交
染色体
三体
生物
移植
内科学
染色体异常
多发性骨髓瘤
肿瘤科
造血
细胞遗传学
血液学
干细胞
17号染色体(人)
总体生存率
核型
非整倍体
造血干细胞移植
医学
染色体分析
生存分析
染色体异常
7号染色体(人类)
自体干细胞移植
遗传学
无进展生存期
三体8
免疫学
单核苷酸多态性
造血细胞
癌症研究
骨髓
基因型
存活率
病理
遗传异质性
作者
Zhao Zeng,Jiao Lu,Jingjing Shang,鸿寅 游,Qingrong Wang,Lijun Wen,Qian Wang,Wanhui Yan,Chunxiao Wu,Panfeng Wang,Lian Bai,Song Lee Jin,Lingzhi Yan,Suning Chen,Depei Wu,Jinlan Pan,Chengcheng Fu
摘要
Summary Hyperdiploidy (HRD) is the most common genetic subtype in multiple myeloma (MM) but with significant prognostic heterogeneity. In this integrated Single Nucleotide Polymorphism (SNP‐array) and Fluorescence In Situ Hybridization (FISH) analysis of 694 newly diagnosed Chinese MM patients, a modal chromosome count >49 predicted superior overall survival (OS, p = 0.0062) and progression‐free survival (PFS, p = 0.00037), outperforming other metrics. Gain of chromosome 3 was favourable for OS ( p = 0.0024) and PFS ( p = 0.00078). Notably, HRD improved OS in patients with isolated 1q21 + ( p = 0.011) but not in those harbouring high‐risk abnormalities (t(4;14), t(14;16), 17p − or 1p32 − ). The prognostic value of modal count was cytogenetic abnormality (CA)‐dependent: in HRD without high‐risk CAs, >49 conferred better OS ( p = 0.01) and PFS ( p = 0.001); in isolated 1q21 + , a favourable trend was observed; but no discrimination in other high‐risk CAs. Autologous haematopoietic stem cell transplantation (AHSCT) significantly improved OS ( p = 0.014) and showed a PFS trend ( p = 0.062) only in HRD patients without high‐risk CAs and with >49 chromosomes. In conclusion, modal chromosome count >49 and chromosome 3 gain are robust favourable markers in HRD. HRD provides survival benefit in isolated 1q21 + . FISH‐based detection of trisomy 3 may offer a rapid, economical alternative for risk assessment of HRD. AHSCT benefit is restricted to low‐risk HRD with higher ploidy.
科研通智能强力驱动
Strongly Powered by AbleSci AI